Zepbound for sleep apnea

In late 2024, the FDA approved Zepbound (tirzepatide) for a new indication: the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity. Zepbound is a dual GIP/GLP-1 receptor agonist — already approved for chronic weight management — and is now the first medication approved to treat obstructive sleep apnea directly. This is a development with significant implications for patients who live with both conditions.

For patients at PEAK who have been managing obesity alongside sleep apnea, this approval opens a new treatment pathway — and potentially a new route to insurance coverage. Here is what you need to know.

A new FDA-approved indication

Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses during sleep, causing breathing interruptions that fragment sleep and reduce oxygen levels. It affects an estimated 30 million adults in the United States, and the majority of those cases are directly linked to excess body weight.

Until now, the standard treatments for OSA have been mechanical — continuous positive airway pressure (CPAP) devices, oral appliances, and in some cases surgery. There was no FDA-approved medication targeting the condition itself. That changed with the approval of Zepbound for moderate-to-severe OSA in adults with obesity.

The approval was based on clinical trial data showing that tirzepatide significantly reduced the severity of sleep apnea as measured by the apnea-hypopnea index (AHI), the standard metric used to diagnose and classify OSA severity.

How weight loss improves sleep apnea

The relationship between excess weight and obstructive sleep apnea is well established and directly mechanical. When a person carries excess weight, particularly around the neck, throat, and upper body, that weight physically contributes to airway obstruction during sleep.

Here is how excess weight drives OSA:

• Fat deposits around the upper airway. Excess adipose tissue in the pharyngeal area narrows the airway, making it more susceptible to collapse during the muscle relaxation that occurs with sleep.
• Increased abdominal pressure. Abdominal obesity pushes the diaphragm upward, reducing lung volume and further compromising airway stability.
• Systemic inflammation. Obesity is associated with chronic low-grade inflammation, which can cause swelling in airway tissues and worsen obstruction.
• Central nervous system effects. Excess weight can affect the brain’s respiratory control centers, altering the signaling that keeps the airway open during sleep.

When patients lose weight, these mechanical and inflammatory factors improve. Fat deposits around the airway decrease, lung volume increases, inflammation reduces, and the airway becomes less prone to collapse. This is why weight loss has long been recommended as a first-line treatment for obesity-related OSA — and why a medication that produces significant, sustained weight loss can meaningfully improve sleep apnea outcomes.

The clinical evidence

The FDA approval was supported by the SURMOUNT-OSA clinical trial program, which studied tirzepatide specifically in patients with moderate-to-severe obstructive sleep apnea and obesity.

The trials demonstrated significant improvements across multiple measures:

• AHI reduction. Patients treated with tirzepatide showed a significant decrease in their apnea-hypopnea index, the primary measure of sleep apnea severity. AHI counts the number of times per hour that breathing partially or completely stops during sleep.
• Weight loss. Participants experienced meaningful weight reduction, which correlated with improvements in sleep apnea severity.
• Quality of life. Patients reported improvements in daytime sleepiness, sleep quality, and overall quality of life measures.
• Oxygen levels. Nighttime oxygen saturation improved in treated patients, reflecting fewer and less severe breathing interruptions.

The clinical data showed that reductions in AHI correlated with the degree of weight loss, reinforcing the mechanistic link between excess weight and airway obstruction. For some patients, the improvement was enough to move them from severe OSA into moderate or even mild categories.

Who qualifies

The FDA approval for Zepbound’s sleep apnea indication applies to a specific patient population. To qualify, you need to meet both of the following criteria:

• Diagnosed moderate-to-severe obstructive sleep apnea. This means an AHI of 15 or greater, confirmed by polysomnography (an in-lab sleep study) or a validated home sleep apnea test (HSAT).
• Obesity. A body mass index (BMI) of 30 or higher.

Both conditions must be documented. A self-reported history of snoring or daytime sleepiness is not sufficient — a formal sleep study is required to establish the diagnosis and severity of OSA.

It is worth noting that many patients who are being treated for obesity at PEAK may already have undiagnosed sleep apnea. Symptoms like loud snoring, waking up gasping, excessive daytime sleepiness, morning headaches, and difficulty concentrating can all point to OSA. If you are experiencing any of these, tell your clinician — a simple screening questionnaire can help determine whether a sleep study is warranted.

Insurance implications

This is where the new indication becomes particularly meaningful for patients. Because the FDA approved Zepbound for sleep apnea as a separate indication from chronic weight management, it follows a different formulary and coverage pathway with insurance carriers.

Here is why that matters:

• Many insurance plans exclude weight loss medications. A significant number of employer-sponsored and commercial plans have explicit exclusions for anti-obesity medications. If your plan has this exclusion, a prescription for Zepbound written for weight management would be denied.
• The sleep apnea indication is not a weight loss medication claim. When Zepbound is prescribed for the treatment of obstructive sleep apnea, it is being prescribed for a respiratory condition — not for weight management. This means it may bypass the weight loss exclusion entirely.
• Different prior authorization criteria. Insurance companies set prior authorization requirements based on the indication. The sleep apnea indication has its own set of criteria, which may be more favorable for certain patients than the weight management criteria.

At PEAK, our team handles insurance verification and prior authorization for every patient. We will determine which indication provides the best pathway for your specific plan, prepare the necessary clinical documentation, and submit the authorization. If you have both obesity and diagnosed OSA, we will evaluate whether the sleep apnea indication offers a more favorable coverage route.

What this means for patients

If you have both obesity and obstructive sleep apnea, Zepbound may now address both conditions with a single medication. This is a meaningful shift from the previous treatment model, where OSA and obesity were treated as separate conditions requiring separate interventions.

Consider the traditional approach:

• A CPAP machine to manage the airway obstruction during sleep
• A separate weight management program to address the underlying obesity
• Ongoing management of both, often with limited coordination between providers

With the new indication, a single medication can reduce the severity of sleep apnea while simultaneously producing the weight loss that addresses the root cause. For many patients, this means fewer breathing interruptions at night, better sleep quality, less daytime fatigue, and meaningful improvement in overall health.

This does not necessarily mean you will stop using your CPAP. Many patients will continue using CPAP alongside Zepbound, particularly early in treatment. But as weight decreases and AHI improves, some patients may be able to reduce their reliance on CPAP or transition to less intensive interventions. Your sleep medicine provider and PEAK clinician can coordinate on this as your treatment progresses.

Getting started

If you think you may qualify for Zepbound under the sleep apnea indication, here is the process at PEAK:

• Clinical evaluation. Your PEAK clinician will review your medical history, current medications, BMI, and sleep apnea status. If you have an existing OSA diagnosis with documented sleep study results, bring that documentation to your visit.
• Sleep study documentation. If you do not have a recent sleep study, we can help coordinate one. You will need polysomnography or a validated home sleep test showing an AHI of 15 or greater to qualify under this indication.
• Insurance verification. Our team will verify your insurance benefits and determine the optimal indication for submitting prior authorization — whether that is the sleep apnea indication, the chronic weight management indication, or both.
• Prior authorization submission. We prepare and submit all clinical documentation required for prior authorization, including sleep study results, BMI documentation, and any supporting medical records.
• Treatment initiation. Once approved, you begin Zepbound with the same dose titration schedule and clinical monitoring that all PEAK patients receive. We track both your weight management progress and your sleep apnea symptoms over time.

The sleep apnea indication is still new, and insurance coverage policies are evolving. Our team stays current on formulary changes and prior authorization requirements across major carriers so you do not have to manage that complexity on your own.

Important safety information: Zepbound carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Tirzepatide has also been associated with pancreatitis; discontinue promptly if pancreatitis is suspected and seek medical attention for severe abdominal pain that does not go away. Gallbladder-related events, including gallstones, have been reported. Discuss your full medical history with your clinician before starting treatment.

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.